The U.S. Self-monitoring Blood Glucose Devices Market was valued at USD 7 billion in 2024 and is estimated to grow at a CAGR of 11.6% to reach USD 20.3 billion by 2034.
The growth is driven by the rising prevalence of diabetes, ongoing technological advancements in SMBG devices, and strong policy and reimbursement support. SMBG devices allow individuals with diabetes to monitor their blood sugar levels regularly, enabling better disease management and informed decisions regarding diet, physical activity, and medication. Government programs like Medicare and Medicaid, along with private insurance coverage, are increasingly supporting these advanced devices, lowering out-of-pocket costs for patients. This financial backing encourages healthcare providers to recommend SMBG devices more widely, expanding access to reliable diabetes management tools. SMBG devices, including blood glucose meters, rely on small blood samples collected via lancets and test strips to deliver accurate glucose readings, supporting daily self-care routines.
The consumables segment was valued at USD 4.2 billion in 2024. Test strips and lancets are essential for daily glucose monitoring and are available over the counter for easy accessibility. Test strips are single-use consumables that collect blood samples for accurate measurement, and their compact design allows patients to monitor glucose levels conveniently at home, work, or while traveling.
The type 1 diabetes segment held a 20.4% share in 2024. Type 1 diabetes is an autoimmune condition that destroys insulin-producing beta cells, resulting in insufficient insulin levels. Regular self-monitoring using SMBG devices is critical for managing blood glucose levels. These devices allow multiple daily checks, helping patients adjust insulin dosage, diet, and exercise, detect fluctuations early, and reduce the risk of severe complications.
The hospitals segment held a 21.5% share in 2024. They act as primary centers for diabetes care, offering diagnosis, treatment initiation, and ongoing monitoring. Equipped with trained professionals and advanced diagnostic technologies, hospitals are central to the adoption of high-tech SMBG solutions. Reimbursement programs and Medicare support further enhance hospitals’ ability to integrate advanced glucose monitoring devices into patient care.
Major players in the U.S. Self-monitoring Blood Glucose Devices Market include Abbott Laboratories, AgaMatrix, All Medicus, Arkray, Ascensia Diabetes Care Holdings, B. Braun Melsungen, Bionime Corporation, DarioHealth, F. Hoffmann-La Roche, LifeScan, Nova Biomedical, Omnis Health, Sanofi, Sinocare, and Ypsomed Holding. Key strategies employed by companies in the U.S. Self-monitoring Blood Glucose Devices Market include continuous investment in R&D to enhance accuracy, usability, and connectivity of devices, launching innovative products that integrate AI or digital health platforms, and forming partnerships with hospitals, pharmacies, and insurers to expand distribution channels. Companies also focus on patient education programs, subscription-based consumables models, and strategic acquisitions to diversify offerings and strengthen market presence.
This product will be delivered within 2-4 business days.
The growth is driven by the rising prevalence of diabetes, ongoing technological advancements in SMBG devices, and strong policy and reimbursement support. SMBG devices allow individuals with diabetes to monitor their blood sugar levels regularly, enabling better disease management and informed decisions regarding diet, physical activity, and medication. Government programs like Medicare and Medicaid, along with private insurance coverage, are increasingly supporting these advanced devices, lowering out-of-pocket costs for patients. This financial backing encourages healthcare providers to recommend SMBG devices more widely, expanding access to reliable diabetes management tools. SMBG devices, including blood glucose meters, rely on small blood samples collected via lancets and test strips to deliver accurate glucose readings, supporting daily self-care routines.
The consumables segment was valued at USD 4.2 billion in 2024. Test strips and lancets are essential for daily glucose monitoring and are available over the counter for easy accessibility. Test strips are single-use consumables that collect blood samples for accurate measurement, and their compact design allows patients to monitor glucose levels conveniently at home, work, or while traveling.
The type 1 diabetes segment held a 20.4% share in 2024. Type 1 diabetes is an autoimmune condition that destroys insulin-producing beta cells, resulting in insufficient insulin levels. Regular self-monitoring using SMBG devices is critical for managing blood glucose levels. These devices allow multiple daily checks, helping patients adjust insulin dosage, diet, and exercise, detect fluctuations early, and reduce the risk of severe complications.
The hospitals segment held a 21.5% share in 2024. They act as primary centers for diabetes care, offering diagnosis, treatment initiation, and ongoing monitoring. Equipped with trained professionals and advanced diagnostic technologies, hospitals are central to the adoption of high-tech SMBG solutions. Reimbursement programs and Medicare support further enhance hospitals’ ability to integrate advanced glucose monitoring devices into patient care.
Major players in the U.S. Self-monitoring Blood Glucose Devices Market include Abbott Laboratories, AgaMatrix, All Medicus, Arkray, Ascensia Diabetes Care Holdings, B. Braun Melsungen, Bionime Corporation, DarioHealth, F. Hoffmann-La Roche, LifeScan, Nova Biomedical, Omnis Health, Sanofi, Sinocare, and Ypsomed Holding. Key strategies employed by companies in the U.S. Self-monitoring Blood Glucose Devices Market include continuous investment in R&D to enhance accuracy, usability, and connectivity of devices, launching innovative products that integrate AI or digital health platforms, and forming partnerships with hospitals, pharmacies, and insurers to expand distribution channels. Companies also focus on patient education programs, subscription-based consumables models, and strategic acquisitions to diversify offerings and strengthen market presence.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 8 Company Profiles
Companies Mentioned
The companies profiled in this U.S. Self-monitoring Blood Glucose Devices market report include:- Abbott Laboratories
- AgaMatrix
- All Medicus
- Arkray
- Ascensia Diabetes Care Holdings
- B. Braun Melsungen
- Bionime Corporation
- DarioHealth
- F. Hoffmann-La Roche
- LifeScan
- Nova Biomedical
- Omnis Health
- Sanofi
- Sinocare
- Ypsomed Holding
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 62 |
| Published | October 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 7 Billion |
| Forecasted Market Value ( USD | $ 20.3 Billion |
| Compound Annual Growth Rate | 11.6% |
| Regions Covered | United States |
| No. of Companies Mentioned | 16 |
